

Cyrielle Caussy

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1480080/publications.pdf>

Version: 2024-02-01

43
papers

3,478
citations

279798
23
h-index

289244
40
g-index

45
all docs

45
docs citations

45
times ranked

5004
citing authors

#	ARTICLE	IF	CITATIONS
1	Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease. <i>Cell Metabolism</i> , 2017, 25, 1054-1062.e5.	16.2	748
2	Noninvasive, Quantitative Assessment of Liver Fat by MRIâ€PDF as an Endpoint in NASH Trials. <i>Hepatology</i> , 2018, 68, 763-772.	7.3	299
3	Magnetic Resonance vs Transient Elastography Analysis of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Pooled Analysis of Individual Participants. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 630-637.e8.	4.4	254
4	Optimal threshold of controlled attenuation parameter with MRIâ€PDF as the gold standard for the detection of hepatic steatosis. <i>Hepatology</i> , 2018, 67, 1348-1359.	7.3	250
5	A gut microbiome signature for cirrhosis due to nonalcoholic fatty liver disease. <i>Nature Communications</i> , 2019, 10, 1406.	12.8	218
6	Prevalence of obesity among adult inpatients with COVID-19 in France. <i>Lancet Diabetes and Endocrinology</i> , the, 2020, 8, 562-564.	11.4	194
7	A Universal Gut-Microbiome-Derived Signature Predicts Cirrhosis. <i>Cell Metabolism</i> , 2020, 32, 878-888.e6.	16.2	167
8	Nonalcoholic fatty liver disease with cirrhosis increases familial risk for advanced fibrosis. <i>Journal of Clinical Investigation</i> , 2017, 127, 2697-2704.	8.2	137
9	Obesity is Associated with Severe Forms of COVIDâ€19. <i>Obesity</i> , 2020, 28, 1175-1175.	3.0	130
10	Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges. <i>Gut</i> , 2020, 69, 1877-1884.	12.1	127
11	Magnetic Resonance Imaging Proton Density Fat Fraction Associates With Progression of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. <i>Gastroenterology</i> , 2018, 155, 307-310.e2.	1.3	113
12	EASLâ€EASDâ€EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease in severely obese people: do they lead to over-referral?. <i>Diabetologia</i> , 2017, 60, 1218-1222.	6.3	95
13	Serum bile acid patterns are associated with the presence of NAFLD in twins, and doseâ€dependent changes with increase in fibrosis stage in patients with biopsyâ€proven NAFLD. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 183-193.	3.7	80
14	The Relationship Between Type 2 Diabetes, NAFLD, and Cardiovascular Risk. <i>Current Diabetes Reports</i> , 2021, 21, 15.	4.2	78
15	Relationship between obesity and severe <sc>COVID</sc>â€19 outcomes in patients with type 2 diabetes: Results from the <sc>CORONADO</sc> study. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 391-403.	4.4	69
16	An APOA5 3â€2 UTR Variant Associated with Plasma Triglycerides Triggers APOA5 Downregulation by Creating a Functional miR-485-5p Binding Site. <i>American Journal of Human Genetics</i> , 2014, 94, 129-134.	6.2	58
17	Serum metabolites detect the presence of advanced fibrosis in derivation and validation cohorts of patients with non-alcoholic fatty liver disease. <i>Gut</i> , 2019, 68, 1884-1892.	12.1	48
18	Association Between Obesity and Discordance in Fibrosis Stage Determination by Magnetic Resonance vs Transient Elastography in Patients With Nonalcoholic Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1974-1982.e7.	4.4	46

#	ARTICLE	IF	CITATIONS
19	Prospective, Same-Day, Direct Comparison of Controlled Attenuation Parameter With the M vs the XL Probe in Patients With Nonalcoholic Fatty Liver Disease, Using Magnetic Resonance Imagingâ€“Proton Density Fat Fraction as the Standard. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1842-1850.e6.	4.4	37
20	An artificial neural network to predict resting energy expenditure in obesity. <i>Clinical Nutrition</i> , 2018, 37, 1661-1669.	5.0	32
21	PPAR-Targeted Therapies in the Treatment of Non-Alcoholic Fatty Liver Disease in Diabetic Patients. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4305.	4.1	28
22	Glyphosate Excretion is Associated With Steatohepatitis and Advanced Liver Fibrosis in Patients With Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 741-743.	4.4	27
23	Liver Stiffness Severity is Associated With Increased Cardiovascular Risk in Patients With Type 2 Diabetes. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 744-746.e1.	4.4	26
24	BMI and pneumonia outcomes in critically ill COVIDâ€“19 patients: An international multicenter study. <i>Obesity</i> , 2021, 29, 1477-1486.	3.0	24
25	Multiple microRNA regulation of lipoprotein lipase gene abolished by 3â€“UTR polymorphisms in a triglyceride-lowering haplotype harboring p.Ser474Ter. <i>Atherosclerosis</i> , 2016, 246, 280-286.	0.8	23
26	Collagen Formation Assessed by Nâ€“Terminal Propeptide of Type 3 Procollagen Is a Heritable Trait and Is Associated With Liver Fibrosis Assessed by Magnetic Resonance Elastography. <i>Hepatology</i> , 2019, 70, 127-141.	7.3	21
27	New rare genetic variants of LMF1 gene identified in severe hypertriglyceridemia. <i>Journal of Clinical Lipidology</i> , 2018, 12, 1244-1252.	1.5	19
28	Management of diabetes mellitus in patients with cirrhosis: An overview and joint statement. <i>Diabetes and Metabolism</i> , 2021, 47, 101272.	2.9	18
29	Alterations in plasma triglycerides lipolysis in patients with history of multifactorial chylomicronemia. <i>Atherosclerosis</i> , 2017, 265, 22-28.	0.8	12
30	Magnetic resonanceâ€“based biomarkers in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. <i>Endocrinology, Diabetes and Metabolism</i> , 2020, 3, e00134.	2.4	11
31	Differences between current clinical guidelines for screening, diagnosis and management of nonalcoholic fatty liver disease and real-world practice: a targeted literature review. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 1253-1266.	3.0	9
32	Comparison of clinical prediction rules for ruling out cirrhosis in nonalcoholic fatty liver disease (<sc>NAFLD</sc>). <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 1441-1451.	3.7	9
33	History of bariatric surgery and COVIDâ€“19 outcomes in patients with type 2 diabetes: Results from the CORONADO study. <i>Obesity</i> , 2022, 30, 599-605.	3.0	7
34	Lack of evidence for a liver or intestinal miRNA regulation involved in the hypertriglyceridemic effect of APOC3 3â€“UTR variant SstI. <i>Atherosclerosis</i> , 2016, 255, 6-10.	0.8	6
35	Should We Screen High-Risk Populations for NAFLD?. <i>Current Hepatology Reports</i> , 2019, 18, 433-443.	0.9	6
36	Harmonic wideband simultaneous dualâ€“frequency MR Elastography. <i>NMR in Biomedicine</i> , 2021, 34, e4442.	2.8	2

#	ARTICLE	IF	CITATIONS
37	Short echo time dual-frequency MR Elastography with Optimal Control RF pulses. Scientific Reports, 2022, 12, 1406.	3.3	2
38	Editorial: screening for hepatocellular carcinoma in <scp>NAFLD</scp>”towards abbreviated <scp>MRI</scp> alternative in patients with obesity?. Alimentary Pharmacology and Therapeutics, 2022, 55, 1210-1211.	3.7	2
39	Reply. Clinical Gastroenterology and Hepatology, 2019, 17, 2140.	4.4	0
40	Non-alcoholic fatty liver disease and chronic kidney disease: renal benefit with liver stiffness assessment?. Diabetes and Metabolism, 2020, 46, 259-260.	2.9	0
41	La st�atopathie dysm�tabolique ou NASH�: faut-il d�pister les patients � haut risque atteints de diab�te de type 2�ou d��mob�sit��?. Nutrition Clinique Et Metabolisme, 2020, 34, 122-129.	0.5	0
42	Undernourished patients do not have increased risk of severe COVID-19 outcomes. Clinical Nutrition Open Science, 2022, , .	1.3	0
43	Letter: non�invasive prediction models to exclude cirrhosis in <scp>NAFLD</scp> � not everyone fits the mould. Authors' reply. Alimentary Pharmacology and Therapeutics, 2022, 56, 182-183.	3.7	0